Article Text

Download PDFPDF
New agents for sickle cell disease: patient perceptions of benefit in the real world
  1. Robert T Means
  1. Internal Medicine and Pathology, James H Quillen College of Medicine, East Tennessee State University, Johnson City, Tennessee, USA
  1. Correspondence to Dr Robert T Means, Internal Medicine, James H Quillen College of Medicine, East Tennessee State University, Johnson City, TN 37614, USA; meansr{at}etsu.edu

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Sickle cell disease (SCD) is one of the most important monogeneic diseases in the world, causing significant morbidity and mortality and consuming substantial healthcare resources.1 SCD results from a single amino acid substitution in the β-globin chain, leading to sickle hemoglobin (HbS). In oxygen-limited settings, HbS forms polymers that lead to the characteristic sickle-shaped erythrocytes and also to changes in the erythrocyte membrane. The pathological features of SCD result from a combination of vaso-occlusive events precipitated both by abnormal erythrocyte morphology and the increased expression of adhesion molecules on its outer membrane; accelerated hemolysis that can deplete nitric oxide and that leads to anemia; and a high level of endogenous inflammatory activation associated …

View Full Text

Footnotes

  • Contributors RTM is the sole contributor of this work.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests RTM is an Associate Editor for the Journal of Investigate Medicine. No other competing interests declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles